Physician profile
David A Scott
NPI 1760478465
$7,775.13
in general payments reported to CMS, 2019-2025
29 companies · $696 in 2025
The $696 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,278 · 2020: $802 · 2021: $987 · 2022: $1,496 · 2023: $1,466 · 2024: $1,050 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,195.11 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,308.58 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,399.69 | 2019-2025 | Entyvio |
| Pfizer INC. | $1,205.92 | 2019-2024 | |
| Janssen Biotech, INC. | $562.92 | 2019-2025 | Stelara, Tremfya |
| Celgene Corporation | $467.18 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $391.80 | 2022-2025 | Epclusa, Vemlidy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.25 | 2019-2023 | Xifaxan |
| Boston Scientific Corporation | $314.74 | 2023-2025 | X-Tack Endoscopic Helix Tacking System, Compliance Endokit, Resolution 360 Ultra Clip |
| Janssen Scientific Affairs, LLC | $82.30 | 2024 | Stelara |
| Phathom Pharmaceuticals, INC. | $66.80 | 2024-2025 | Voquezna |
| Amgen INC. | $65.97 | 2021-2022 | |
| Ucb, INC. | $55.59 | 2019-2020 | |
| Erbe USA INC | $50.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $48.34 | 2023 | Dupixent |
| Braintree Laboratories, INC. | $47.21 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $40.23 | 2020 | |
| Intercept Pharmaceuticals, INC. | $39.39 | 2020-2021 | |
| Evoke Pharma, INC. | $35.79 | 2022 | |
| Ferring Pharmaceuticals INC. | $33.46 | 2019-2020 | |
| Redhill Biopharma INC. | $31.45 | 2021-2023 | |
| Genzyme Corporation | $31.02 | 2023 | |
| Creo Medical INC. | $26.80 | 2024 | Speedboat Ultraslim (Sb1l) |
| Dynavax Technologies Corporation | $24.14 | 2021 | |
| Ardelyx, INC. | $23.77 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $20.85 | 2021 | |
| Madrigal Pharmaceuticals | $16.25 | 2024 | Resmetirom |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Allergan, INC. | $13.97 | 2019 | |
| Daiichi Sankyo INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.